Dear Administrator Oz,
The Endocrine Society writes in opposition to the proposed rule, which would deny Medicaid and CHIP funding for certain types of care for patients under age 18 who have been diagnosed with gender dysphoria. The Endocrine Society believes that health care decisions should be made by qualified medical professionals in partnership with patients and their families, based on scientific evidence and the individualized needs and values of the patient and their family. We oppose the proposed rule because it overrides this approach for patients under age 18 who depend on Medicaid and CHIP for their care. We also oppose the proposed rule because it misstates our clinical practice guidelines and the consensus among the medical professional community regarding options for the treatment of gender dysphoria.
